University of Hawaii Cancer Center, Honolulu, HI.
Wake Forest University School of Medicine, Winston-Salem, NC.
JCO Oncol Pract. 2024 Feb;20(2):239-246. doi: 10.1200/OP.23.00501. Epub 2024 Jan 4.
Oncology advanced practice providers (APPs), including nurse practitioners, clinical nurse specialists, physician assistants, and clinical pharmacists, contribute significantly to quality cancer care. Understanding the research-related roles of APPs in the National Cancer Institute's (NCI) Community Oncology Research Program (NCORP) could lead to enhanced protocol development, trial conduct, and accrual.
The 2022 NCORP Landscape Assessment Survey asked two questions about the utilization and roles of APPs in the NCORP.
A total of 271 practice groups completed the 2022 survey, with a response rate of 90%. Of the 259 nonpediatric exclusive practice groups analyzed in this study, 92% used APPs for clinical care activities and 73% used APPs for research activities. APPs most often provided clinical care for patients enrolled in trials (97%), followed by assistance with coordination (65%), presenting/explaining clinical trials (59%), screening patients (49%), ordering investigational drugs (37%), and consenting participants (24%). Some groups reported APPs as an enrolling investigator (18%) and/or participating in institutional oversight/selection of trials (15%). Only 5% of NCORP sites reported APPs as a site primary investigator for trials, and very few (3%) reported APPs participating in protocol development.
Practice groups report involving APPs in clinical research within the NCORP network; however, opportunities for growth exists. As team-based care has enhanced clinical practice in oncology, this same approach can be used to enhance successful research. Suggested strategies include supporting APP research-related time, recognition, and education. The findings of this survey and subsequent recommendations may be applied to all adult oncology practices that participate in clinical research.
肿瘤学高级实践提供者(APP),包括护士从业者、临床护理专家、医师助理和临床药师,为癌症护理质量做出了重要贡献。了解 APP 在国家癌症研究所(NCI)社区肿瘤学研究计划(NCORP)中的研究相关角色,可能会促进方案制定、试验实施和入组。
2022 年 NCORP 全景评估调查询问了两个关于 APP 在 NCORP 中的利用和角色的问题。
共有 271 个实践小组完成了 2022 年的调查,回复率为 90%。在本研究分析的 259 个非儿科专属实践组中,92%的组使用 APP 进行临床护理活动,73%的组使用 APP 进行研究活动。APP 最常为参与试验的患者提供临床护理(97%),其次是协助协调(65%)、介绍/解释临床试验(59%)、筛选患者(49%)、开调查性药物(37%)和同意参与者(24%)。一些小组报告 APP 作为入组研究者(18%)和/或参与机构监督/选择试验(15%)。只有 5%的 NCORP 站点报告 APP 作为试验的主要研究者,很少(3%)的站点报告 APP 参与方案制定。
实践组报告在 NCORP 网络内将 APP 纳入临床研究;然而,仍有增长的空间。随着基于团队的护理在肿瘤学中增强了临床实践,这种方法也可以用于增强成功的研究。建议的策略包括支持 APP 与研究相关的时间、认可和教育。这项调查的结果和随后的建议可能适用于所有参与临床研究的成人肿瘤学实践。